Effects of selective cyclooxygenase-2 and nonselective cyclooxygenase inhibition on ischemic myocardium

Journal of Thoracic and Cardiovascular Surgery

Volumn 140, Issue 5, 2010, Pages 1143-1152

  Robich, Michael P ^a,b   Chu, Louis M ^a   Feng, Jun ^c   Burgess, Thomas A ^c   Laham, Roger J ^b   Bianchi, Cesario ^c   Sellke, Frank W ^a,b,c  

^a BROWN UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c RHODE ISLAND HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ENDOSTATIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NAPROXEN; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE INHIBITOR; VASCULOTROPIN; ANGIOGENIC PROTEIN; AUTACOID; CYCLOOXYGENASE 2; PYRAZOLE DERIVATIVE; SULFONAMIDE; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

ANGIOCARDIOGRAPHY; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; COLLATERAL CIRCULATION; CONTROLLED STUDY; CORONARY ARTERY CIRCUMFLEX BRANCH; CORONARY ARTERY CONSTRICTION; HEART; HEART FUNCTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; MEAN ARTERIAL PRESSURE; MICROVASCULATURE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTAGLANDIN BLOOD LEVEL; PROTEIN EXPRESSION; SWINE; ANIMAL; BLOOD PRESSURE; COMPARATIVE STUDY; CORONARY ARTERY BLOOD FLOW; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; HEART MUSCLE; HEART RATE; METABOLISM; MICROCIRCULATION; MINIPIG; MYOCARDIAL ISCHEMIA; MYOCARDIAL PERFUSION IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; TIME; TOXICITY;

ANGIOGENIC PROTEINS; ANIMALS; APOPTOSIS; BLOOD PRESSURE; COLLATERAL CIRCULATION; CORONARY ANGIOGRAPHY; CORONARY CIRCULATION; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART RATE; INFLAMMATION MEDIATORS; MICROCIRCULATION; MYOCARDIAL ISCHEMIA; MYOCARDIAL PERFUSION IMAGING; MYOCARDIUM; NAPROXEN; NEOVASCULARIZATION, PHYSIOLOGIC; OXIDATIVE STRESS; PROSTAGLANDINS; PYRAZOLES; SULFONAMIDES; SWINE; SWINE, MINIATURE; TIME FACTORS; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS; VENTRICULAR FUNCTION, LEFT;

EID: 77957979764     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2010.06.057     Document Type: Article

References (25)

1. K.D. Coon, L.J. Inge, K. Swetel, V. Felton, P. Stafford, and R.M. Bremner Genomic characterization of the inflammatory response initiated by surgical intervention and the effect of perioperative cyclooxygenase 2 blockade J Thorac Cardiovasc Surg 139 2010 1253 1260 1260.e1-2
2. C. Bombardier, L. Laine, A. Reicin, D. Shapiro, R. Burgos-Vargas, and B. Davis Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group N Engl J Med 343 2000 1520 1528 2 p following 1528
3. M.E. Farkouh, and B.P. Greenberg An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs Am J Cardiol 103 2009 1227 1237
4. E. Ott, N.A. Nussmeier, P.C. Duke, R.O. Feneck, R.P. Alston, and M.C. Snabes Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery J Thorac Cardiovasc Surg 125 2003 1481 1492
5. Y. Cheng, M. Wang, Y. Yu, J. Lawson, C.D. Funk, and G.A. Fitzgerald Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function J Clin Invest 116 2006 1391 1399
6. G. Wu, J. Luo, J.S. Rana, R. Laham, F.W. Sellke, and J. Li Involvement of COX-2 in VEGF-induced angiogenesis via P38 and JNK pathways in vascular endothelial cells Cardiovasc Res 69 2006 512 519
7. P. Meier, S. Gloekler, R. Zbinden, S. Beckh, S.F. de Marchi, and S. Zbinden Beneficial effect of recruitable collaterals: a 10-year follow-up study in patients with stable coronary artery disease undergoing quantitative collateral measurements Circulation 116 2007 975 983
8. M. Tofukuji, C. Metais, J. Li, A. Franklin, M. Simons, and F.W. Sellke Myocardial VEGF expression after cardiopulmonary bypass and cardioplegia Circulation 98 19 Suppl 1998 II242 II248
9. M. Boodhwani, S. Mieno, J. Feng, N.R. Sodha, R.T. Clements, S.H. Xu, and F.W. Sellke Atorvastatin impairs the myocardial angiogenic response to chronic ischemia in normocholesterolemic swine J Thorac Cardiovasc Surg 135 2008 117 122
10. J.D. Altman, C.L. Klassen, and R.J. Bache Cyclooxygenase blockade limits blood flow to collateral-dependent myocardium during exercise Cardiovasc Res 30 1995 697 704
11. G. Rossoni, M.N. Muscara, G. Cirino, and J.L. Wallace Inhibition of cyclo-oxygenase-2 exacerbates ischaemia-induced acute myocardial dysfunction in the rabbit Br J Pharmacol 135 2002 1540 1546
12. X.Z. Dai, and R.J. Bache Effect of indomethacin on coronary blood flow during graded treadmill exercise in the dog Am J Physiol 247 3 Pt 2 1984 H452 H458
13. D.R. Sorensen, T.A. Read, T. Porwol, B.R. Olsen, R. Timpl, and T. Sasaki Endostatin reduces vascularization, blood flow, and growth in a rat gliosarcoma Neuro Oncol 4 2002 1 8
14. A.G. Johnson, T.V. Nguyen, and R.O. Day Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis Ann Intern Med 121 1994 289 300
15. J. Zhang, E.L. Ding, and Y. Song Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials JAMA 296 2006 1619 1632
16. C.D. Funk, and G.A. FitzGerald COX-2 inhibitors and cardiovascular risk J Cardiovasc Pharmacol 50 2007 470 479
17. A.G. Johnson, T.V. Nguyen, R. Owe-Young, D.J. Williamson, and R.O. Day Potential mechanisms by which nonsteroidal anti-inflammatory drugs elevate blood pressure: the role of endothelin-1 J Hum Hypertens 10 1996 257 261
18. G. Wu, A.P. Mannam, J. Wu, S. Kirbis, J.L. Shie, and C. Chen Hypoxia induces myocyte-dependent COX-2 regulation in endothelial cells: role of VEGF Am J Physiol Heart Circ Physiol 285 2003 H2420 H2429
19. J.H. Lee, H. Koh, M. Kim, J. Park, S.Y. Lee, and S. Lee JNK pathway mediates apoptotic cell death induced by tumor suppressor LKB1 in Drosophila. Cell Death Differ 13 2006 1110 1122
20. K.G. Mendelson, L.R. Contois, S.G. Tevosian, R.J. Davis, and K.E. Paulson Independent regulation of JNK/p38 mitogen-activated protein kinases by metabolic oxidative stress in the liver Proc Natl Acad Sci U S A 93 1996 12908 12913
21. E.P. Ryan, T.P. Bushnell, A.E. Friedman, I. Rahman, and R.P. Phipps Cyclooxygenase-2 independent effects of cyclooxygenase-2 inhibitors on oxidative stress and intracellular glutathione content in normal and malignant human B-cells Cancer Immunol Immunother 57 2008 347 358
22. N. Suematsu, H. Tsutsui, J. Wen, D. Kang, M. Ikeuchi, and T. Ide Oxidative stress mediates tumor necrosis factor-α-induced mitochondrial DNA damage and dysfunction in cardiac myocytes Circulation 107 2003 1418 1423
23. B.F. McAdam, F. Catella-Lawson, I.A. Mardini, S. Kapoor, J.A. Lawson, and G.A. FitzGerald Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2 Proc Natl Acad Sci U S A 96 1999 272 277
24. S.D. Solomon, J.J. McMurray, M.A. Pfeffer, J. Wittes, R. Fowler, and P. Finn Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention N Engl J Med 352 2005 1071 1080
25. S.D. Solomon, J. Wittes, P.V. Finn, R. Fowler, J. Viner, and M.M. Bertagnolli Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis Circulation 117 2008 2104 2113